Skip to main content
Advertisement
Advertisement

KPTI

KPTI logo

Karyopharm Therapeutics Inc.

1.62
USD
Sponsored
-0.11
-6.36%
Sep 25, 15:59 UTC -4
Closed
exchange

After-Market

1.66

+0.04
+2.47%

KPTI Earnings Reports

Positive Surprise Ratio

KPTI beat 25 of 43 last estimates.

58%

Next Report

Date of Next Report
Nov 02, 2026
Estimate for Q3 26 (Revenue/ EPS)
$34.22M
/
-$0.96
Implied change from Q2 26 (Revenue/ EPS)
+2.36%
/
-58.44%
Implied change from Q3 25 (Revenue/ EPS)
-22.31%
/
-74.87%

Karyopharm Therapeutics Inc. earnings per share and revenue

On Aug 13, 2026, KPTI reported earnings of -2.31 USD per share (EPS) for Q2 26, missing the estimate of -1.30 USD, resulting in a -78.16% surprise. Revenue reached 33.43 million, compared to an expected 32.83 million, with a 1.83% difference. The market reacted with a -1.97% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 5 analysts forecast an EPS of -0.96 USD, with revenue projected to reach 34.22 million USD, implying an decrease of -58.44% EPS, and increase of 2.36% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
PharmaCyte Biotech, Inc. Common Stock
Report Date
Sep 14, 2026 For Q1 27
Estimate
-
Actual
-$0.54
Surprise
-
FAQ
For Q2 2026, Karyopharm Therapeutics Inc. reported EPS of -$2.31, missing estimates by -78.16%, and revenue of $33.43M, 1.83% above expectations.
The stock price moved down -1.97%, changed from $2.03 before the earnings release to $1.99 the day after.
The next earning report is scheduled for Nov 02, 2026.
Based on 5 analysts, Karyopharm Therapeutics Inc. is expected to report EPS of -$0.96 and revenue of $34.22M for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement